ENDRA Q4 net loss $1.5M, FDA De Novo review ongoing; Q2 meeting set

ENDRA Life Sciences Inc.

Net loss Q4 2023: $1.5M ($0.17/share) vs $3.3M ($1.04) in Q4 2022.
Full year 2023 net loss $10.1M ($1.58/share) vs $13.2M ($4.56) in 2022.
Cash and cash equivalents $2.8M as of December 31, 2023.
Installed first TAEUS system at King's College Hospital UK for 75-subject clinical study.
FDA De Novo review ongoing; in-person meeting scheduled for Q2 2024 after Additional Information request.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, EPS $0.17 per share.

Period: the quarter and year ended December 31, 2023
Net income: Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share
EPS: $0.17 per share
Result: reported results

Exact text from the filing

Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, compared with a net loss of $3.3 million, or $1.04 per share, in the fourth quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ENDRA Life Sciences Inc. reported the year ended December 31, 2023 results: net income Net loss in 2023 was $10.1 million, or $1.58 per share, EPS $1.58 per share.

Period: the year ended December 31, 2023
Net income: Net loss in 2023 was $10.1 million, or $1.58 per share
EPS: $1.58 per share
Result: reported results

Exact text from the filing

Net loss in 2023 was $10.1 million, or $1.58 per share, compared with a net loss of $13.2 million, or $4.56 per share, in 2022.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-003868

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.